The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday, reports Reuters.
The ailment is a complication of severe near-sightedness that can lead to blindness, it added in a statement.
